Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 50 and up

Mobithron Advance for knee osteoarthritis: long-term effects

Official title: Long-Term Effects of Mobithron Advance on Knee Osteoarthritis

Run by Universiti Sains Malaysia · NCT07323745 · Data updated 2026-11-12

This study tests whether taking Mobithron Advance daily for a year can slow knee OA progression and improve symptoms in adults over 50.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages50 Years and up
SexAll
Enrollment84 (estimated)
SponsorUniversiti Sains Malaysia
Academic / other
Locations1 site (Kota Bharu, Kelantan)
StatusRecruiting
StartedMay 3, 2026
Main results expectedDecember 31, 2026
Study endsOctober 31, 2027
Registry record updatedJune 12, 2026
Trial IDNCT07323745 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 50 with clinically and radiographically confirmed knee OA (Kellgren-Lawrence grades 1–3).

Probably not a fit

Patients with conflicting diagnoses, advanced OA (KL grade 4+), recent knee surgery plans, or exclusion criteria may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm trial conducted at Hospital Universiti Sains Malaysia to assess the long-term safety and potential disease-modifying effects of Mobithron Advance in knee OA with Kellgren-Lawrence grades 1–3. Participants will receive oral Mobithron Advance daily for 12 months, with visits at 3, 6, and 12 months for assessments including pain (VAS), function (WOMAC), and MRI-based cartilage measurements, along with safety labs. Data will be analyzed descriptively and with appropriate longitudinal methods to observe changes over time. The study aims to determine if long-term treatment modifies OA progression and to characterize the safety profile in this population.

Why it matters

Potential benefit: If successful, Mobithron Advance could slow OA progression and reduce pain or functional impairment in knee OA.

How similar studies have gone: Previous studies with similar agents have shown mixed results; this trial explores long-term safety and potential progression modification in a defined KL 1–3 OA population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Males and female patients above 50 years old at the time of recruitment.
* OA Diagnosis: Patients with one or both knee osteoarthritis according to clinical and radiological criteria of the American College of Rheumatology (ACR).
* OA Grade: Kellgren Lawrence grade 1-3

Exclusion Criteria:

* Secondary arthritis (e.g., rheumatoid arthritis, psoriatic arthritis).
* History of joint surgery.
* Patients who received steroid injection treatment within the last 3 months or hyaluronic acid injection treatment within the last 6 months.
* Contraindications to Mobithron Advance (e.g., known allergies, severe liver or kidney disease).
* Patients planning for knee surgery within the research period.
* Patients on pharmacological treatment for osteoarthritis, other than rescue analgesic agent, e.g: glucosamine, chondroitin, oral steroid

Where it's running

  • Hospital Univerisiti Sains Malaysia (HUSM)
    Kota Bharu, Kelantan, Malaysia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Medial knee osteoarthritis: inside vs outside corticosteroid injection

    This study tests whether injecting a steroid inside the knee joint leads to different pain results than injecting it on the outside of the knee in people with medial knee osteoarthritis.

    Recruiting at 5 sites University of Chicago · Bolingbrook, Illinois and 4 other locations · NCT07804446

  • Platelet-rich plasma added to hyaluronic acid for knee osteoarthritis

    This study tests whether a single injection of hyaluronic acid plus autologous platelet-rich plasma helps reduce knee OA symptoms more than hyaluronic acid alone in adults with moderate knee OA.

    Recruiting Implai Sp z o.o · Warsaw, Masovian Voivodeship · NCT07785401

  • Hyaluronic Acid Plus PRP Injection for Knee Osteoarthritis

    This study tests whether a single HA injection combined with a patient’s own PRP is better at easing knee OA pain than HA alone.

    Recruiting Implai Sp z o.o · Chełm, Lublin Voivodeship · NCT07784907

  • Long-acting local pain medicine after knee replacement

    This study tests whether a new extended-release pain medicine (Zynrelef) given around the knee during total knee replacement can reduce pain after surgery better or as well as standard injections or nerve blocks.

    Recruiting Phase 4 Henry Ford Health System · Grosse Pointe Farms, Michigan · NCT07775248

  • Choose to Move Replacement Ready for OA patients waiting for hip or knee replacement

    This program tests a tailored, online version of a 3-month activity and social-connection plan for older adults with hip or knee osteoarthritis who are waiting for joint replacement surgery to see if it improves physical activity and health while they wait.

    Recruiting University of British Columbia · Vancouver, British Columbia · NCT07696650

  • Modular powered knee braces to help move better and reduce knee pain

    A device with partial motor support is being tested in adults with knee OA to see if it can ease pain and reduce effort during daily activities.

    Recruiting University of Michigan · Ann Arbor, Michigan · NCT07673328

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.